Related Experiment Video

Updated: Feb 20, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.6K

Targeting ATR/CHK1 pathway in acute myeloid leukemia to overcome chemoresistance

Laure David1,2,3, Stéphane Manenti1,2,3, Christian Récher2,3,4

  • 1Equipe Labellisée, La Ligue Contre Le Cancer, Toulouse, France.

Molecular & Cellular Oncology
|October 24, 2017
PubMed

Insights

Chemoresistance in acute myeloid leukemia (AML) is a major challenge. This study reveals the ATR/CHK1 pathway is crucial for leukemic cell survival and proliferation, offering new therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Acute myeloid leukemia (AML) frequently relapses due to resistance to existing treatments.
  • Understanding the molecular basis of chemoresistance is critical for developing novel therapeutic strategies.

Purpose of the Study:

  • To investigate the role of the ATR/CHK1 pathway in AML chemoresistance.
  • To identify molecular mechanisms underlying leukemic cell resistance and proliferation.

Main Methods:

  • Analysis of the ATR/CHK1 signaling pathway in leukemic cells.
  • Assessment of genomic stability maintenance mechanisms.

Main Results:

  • The ATR/CHK1 pathway was identified as a key player in AML chemoresistance.
  • This pathway is involved in the proliferation characteristics of leukemic cells.
  • The ATR/CHK1 pathway contributes to maintaining genomic stability in leukemic cells.

Conclusions:

  • Targeting the ATR/CHK1 pathway presents a potential therapeutic strategy for overcoming chemoresistance in AML.
  • Further research into this pathway could lead to improved treatment outcomes for AML patients.
Keywords:
ATR and CHK1 kinasesAcute Myeloid LeukemiaChemoresistanceDNA replicative stress

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

835
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
25
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.2K